A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) after Induction Chemotherapy for Locally Advanced Pancreatic Cancer
Stereotactic body radiotherapy (SBRT) is a form of radiation therapy in which high doses are given very precisely, typically over five or fewer treatments. It has been shown to control tumor growth in patients with locally advanced pancreatic cancer (which has not spread to other organs).
In this study, researchers want to find the most effective dose of SBRT that can be given safely to patients with inoperable locally advanced pancreatic cancer. Progressively higher doses of SBRT will be given to groups of patients who have persistent localized inoperable disease after initial chemotherapy. It is hoped that increasing the dose of SBRT will improve its effectiveness over standard radiation therapy, with fewer side effects.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have locally advanced pancreatic cancer that cannot be surgically removed.
- Patients must have had at least 3 months but no more than 6 months of induction chemotherapy, completed no more than 8 weeks before entering the study.
- Patients who have previously had radiation therapy to the abdomen may not participate.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Marsha Reyngold at 631-623-4267.